GLITISOL Tablet Ref.[28295] Active ingredients: Glibenclamide

Source: Υπουργείο Υγείας (CY)  Revision Year: 2016  Publisher: Remedica Ltd, Aharnon Str.,Limassol Industrial Estate, 3056 Limassol, Cyprus

5.1. Pharmacodynamic properties

Pharmacotherapeutic group: Drugs used in diabetes; Blood glucose lowering drugs, excl. insulins
ATC Code: A10BB01

The pharmacodynamic effect of glibenclamide is to lower blood glucose levels.

Mechanisms proposed for this effect include:

  • Stimulation of insulin release from pancreatic beta-cells
  • Increasing insulin binding receptor density in peripheral tissues

Plasma glucose levels affect the insulin-releasing response to glibenclamide, (a high glucose level increases the response). The minimum active concentration for effect is considered to be 30–50 nanograms/ml glibenclamide.

Investigations of the relationship between insulin, glucose levels and glibenclamide in the hypoglycaemic effect continue.

5.2. Pharmacokinetic properties

A sulphonylurea hypoglycaemic agent rapidly absorbed and inducing its effect within 3 hours with a duration of up to 15 hours although the T½ of drug is 5 to 10 hours. The drug is metabolised extensively in the liver and excreted via bile and urine. It is strongly protein-bound.

5.3. Preclinical safety data

None of clinical relevance.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.